Press Release
Sep 21 2020
Novellus Closes $57M Series C Financing
Read more
Fore Biotherapeutics Enters Pharma Business With BRAF Inhibitor as Lead Product
Press Release
March 11, 2021 11:23 AM EDT
NEW YORK – Fore Biotherapeutics, which last month officially changed its name from NovellusDx, has transitioned to developing its own drugs and is advancing a targeted treatment for cancer patients with certain BRAF tumor mutations not addressed by available options.
Read More
Press Release
Jun 03 2020
Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical StageBRAF Inhibitor
Read more
Press Release
Jul 20 2017
New partnership between Christiana Care’s Gene Editing Institute and NovellusDx speeds progress toward personalized cancer medicine
Read more